ClinicalTrials.Veeva

Menu

TREAT Study - Improving the Interpretation of Troponin Concentrations Following Exercise and Their Clinical Significance

R

Radboud University Medical Center

Status

Active, not recruiting

Conditions

Coronary Artery Disease

Treatments

Other: Exercise exposure

Study type

Observational

Funder types

Other

Identifiers

NCT06295081
NL79864.091.22
112927 (Other Identifier)

Details and patient eligibility

About

The goal of this observational study is to learn about cardiac biomarker release following exercise in amateur athletes.

The main questions it aims to answer are:

Question 1: What are the reference values for exercise-induced cardiac troponin elevations following walking, cycling and running exercise? Hypothesis 1: We hypothesize that the exercise-induced cTn release is different following walking, cycling and running exercise. Therefore, we will establish reference values for post-exercise cTn concentrations across each of these sport types.

Question 2: Is the prevalence of (subclinical) coronary artery disease higher in individuals with high post-exercise cardiac troponin concentrations in comparison to individuals with low post-exercise cardiac troponin concentrations? Hypothesis 2: We hypothesize that athletes with the highest post-exercise cTn concentrations have a higher prevalence of coronary atherosclerosis compared to athletes matched for sex and age with the lowest post-exercise cTn concentrations.

Question 3: What is the association between post-exercise cardiac troponin concentrations and major adverse cardiovascular events (MACE) and mortality during long-term follow-up? Hypothesis 3: We hypothesize that post-exercise cTn concentrations beyond the 99th percentile are associated with an increased risk for MACE and mortality during follow-up.

This study consists of three phases:

Phase 1: two or three visits to the study location for (amongst other measurements) blood draws to assess cardiac troponin concentrations

Phase 2: CT scan of the heart in 10% of participants to assess the prevalence of (subclinicial) coronary artery disease.

Phase 3: longitudinal follow-up to assess the incidence of major adverse cardiovascular events and mortality during 20-year follow-up.

Participants will visit our study centre two, three or four times:

Visit 1: baseline measurements including height, weight, body composition and blood pressure will be obtained and a blood sample will be drawn.

Visit 2: a blood sample will be drawn and activity data will be obtained from participants' own sports watch or bike computer.

Optional visit 3: a blood sample will be drawn. Visit 4: 10% of participants will undergo a cardiac CT scan to assess the prevalence of (subclinical) coronary artery disease.

Full description

For a detailed description, please see the attached study protocol under 'Documents'.

Enrollment

1,015 patients

Sex

All

Ages

40 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

In order to be eligible to participate in this study, a subject must meet all of the following criteria:

  • Participant of an affiliated mass-participation exercise event with a:

    • Walking distance ≥20 km
    • Cycling distance ≥100 km
    • Running distance ≥15 km
  • Age: ≥ 40 and <70 years old

  • Able to understand and perform study related procedures

For Phase 2 of the study (i.e. assessment of (sub)clinical coronary artery disease), the following additional criteria are present:

• Free from (known) cardiovascular diseases

Exclusion criteria

A potential subject who meets any of the following criteria will be excluded from participation in Phase 2 of the study:

  • Renal transplantation in the past
  • Contrast nephropathy in the past
  • estimated glomerular filtration rate (eGFR) < 30 ml/min
  • Atrial fibrillation (heart rhythm disorder)
  • Previous allergic reaction to iodine contrast
  • Participation in other studies involving radiation
  • Not willing to be informed about potential incidental findings from the CT-scan

Trial design

1,015 participants in 3 patient groups

Walkers
Description:
Amateur athletes who perform a walking exercise with a minimum distance of 20 km
Treatment:
Other: Exercise exposure
Runners
Description:
Amateur athletes who perform a running exercise with a minimum distance of 15 km
Treatment:
Other: Exercise exposure
Cyclists
Description:
Amateur athletes who perform a cycling exercise with a minimum distance of 100 km
Treatment:
Other: Exercise exposure

Trial documents
1

Trial contacts and locations

1

Loading...

Central trial contact

IKS Integraal kwaliteitssysteem; Sylvan Janssen, MSc

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems